LIQUIDIA CORPORATION Investing Cash Flow
LIQUIDIA CORPORATION (LQDA) reported Investing Cash Flow of -$15.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-12
- LIQUIDIA CORPORATION net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$12.23M.
- LIQUIDIA CORPORATION net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$2.83M.
- LIQUIDIA CORPORATION net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$4.04M.
- LIQUIDIA CORPORATION net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$911.00K.
- LIQUIDIA CORPORATION net cash provided by (used in) investing activities for fiscal 2025 was -$6.34M.
- LIQUIDIA CORPORATION net cash provided by (used in) investing activities for fiscal 2024 was -$8.44M.
- LIQUIDIA CORPORATION net cash provided by (used in) investing activities for fiscal 2023 was -$11.29M.
- LIQUIDIA CORPORATION net cash provided by (used in) investing activities for fiscal 2022 was -$587.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$12.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$15.06M 10-Q · filed 2026-08-12 | -$19.10M derived: sum of 3 quarters · filed 2026-08-12 | -$20.01M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | -$2.83M 10-Q · filed 2026-05-11 | -$6.87M derived: sum of 2 quarters · filed 2026-05-11 | -$7.78M derived: sum of 3 quarters · filed 2026-05-11 | -$8.84M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | -$4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$4.95M derived: sum of 2 quarters · filed 2026-03-05 | -$6.01M derived: sum of 3 quarters · filed 2026-08-12 | -$6.34M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | -$911.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$1.97M derived: sum of 2 quarters · filed 2026-08-12 | -$2.30M 10-Q · filed 2025-11-03 | -$7.08M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | -$1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$1.39M 10-Q · filed 2026-08-12 | -$6.17M derived: sum of 3 quarters · filed 2026-08-12 | -$7.91M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | -$330.00K 10-Q · filed 2026-05-11 | -$5.11M derived: sum of 2 quarters · filed 2026-05-11 | -$6.86M derived: sum of 3 quarters · filed 2026-05-11 | -$8.15M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$4.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$6.53M derived: sum of 2 quarters · filed 2026-03-05 | -$7.82M derived: sum of 3 quarters · filed 2026-03-05 | -$8.44M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | -$1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$3.04M derived: sum of 2 quarters · filed 2025-11-03 | -$3.66M 10-Q · filed 2025-11-03 | -$3.87M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-06-30 | -$1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.91M 10-Q · filed 2025-08-12 | -$2.12M derived: sum of 3 quarters · filed 2026-03-05 | -$12.60M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-03-31 | -$624.00K 10-Q · filed 2025-05-08 | -$830.00K derived: sum of 2 quarters · filed 2026-03-05 | -$11.30M derived: sum of 3 quarters · filed 2026-03-05 | -$11.55M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2023-12-31 | -$206.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$10.68M derived: sum of 2 quarters · filed 2026-03-05 | -$10.92M derived: sum of 3 quarters · filed 2026-03-05 | -$11.29M 10-K · filed 2026-03-05 | ||||
| 2023-09-30 | -$10.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$10.72M derived: sum of 2 quarters · filed 2024-11-13 | -$11.08M 10-Q · filed 2024-11-13 | -$11.57M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$243.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$607.00K 10-Q · filed 2024-08-07 | -$1.10M derived: sum of 3 quarters · filed 2024-08-07 | -$1.19M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | -$364.00K 10-Q · filed 2024-05-13 | -$855.00K derived: sum of 2 quarters · filed 2024-05-13 | -$949.00K derived: sum of 3 quarters · filed 2024-05-13 | -$951.00K derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | -$491.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$585.00K derived: sum of 2 quarters · filed 2024-03-13 | -$587.00K derived: sum of 3 quarters · filed 2024-03-13 | -$587.00K 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | -$94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$96.00K derived: sum of 2 quarters · filed 2023-11-07 | -$96.00K 10-Q · filed 2023-11-07 | -$116.00K derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$2.00K 10-Q · filed 2023-08-10 | -$22.00K derived: sum of 3 quarters · filed 2023-08-10 | -$22.00K derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-08 | -$20.00K derived: sum of 2 quarters · filed 2023-05-08 | -$20.00K derived: sum of 3 quarters · filed 2023-05-08 | -$55.00K derived: sum of 4 quarters · filed 2023-05-08 | ||||
| 2021-12-31 | -$20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$20.00K derived: sum of 2 quarters · filed 2023-03-20 | -$55.00K derived: sum of 3 quarters · filed 2023-03-20 | -$107.00K 10-K · filed 2023-03-20 | -$107.22K 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$35.00K derived: sum of 2 quarters · filed 2022-11-08 | -$87.00K 10-Q · filed 2022-11-08 | -$87.24K 10-Q · filed 2021-11-03 | $874.03K derived: sum of 4 quarters · filed 2022-11-08 | |||
| 2021-06-30 | -$35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$87.00K 10-Q · filed 2022-08-11 | -$87.24K 10-Q · filed 2021-08-10 | $874.03K derived: sum of 3 quarters · filed 2022-08-11 | $751.53K derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | -$52.00K 10-Q · filed 2022-05-12 | -$52.42K 10-Q · filed 2021-05-13 | $909.03K derived: sum of 2 quarters · filed 2022-05-12 | $786.53K derived: sum of 3 quarters · filed 2022-05-12 | $378.13K derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $961.03K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $838.53K derived: sum of 2 quarters · filed 2022-03-17 | $430.13K derived: sum of 3 quarters · filed 2022-03-17 | $247.91K 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | -$122.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$530.90K derived: sum of 2 quarters · filed 2021-11-03 | -$713.12K 10-Q · filed 2021-11-03 | |||||
| 2020-06-30 | -$408.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$590.62K 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | -$182.22K 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | -$1.85M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |